Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Conventional cost-effectiveness analysis—i.e., assessing pharmaceuticals through a cost per quality-adjusted life year (QALY) framework—originated from a societal commitment to maximize population health given limited resources. This "extra-welfarist" approach has produced pricing and reim...

Descripción completa

Detalles Bibliográficos
Autores principales: Postma, Maarten J., Noone, Declan, Rozenbaum, Mark H., Carter, John A., Botteman, Marc F., Fenwick, Elisabeth, Garrison, Louis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981887/
https://www.ncbi.nlm.nih.gov/pubmed/35382853
http://dx.doi.org/10.1186/s13023-022-02283-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981887/
https://www.ncbi.nlm.nih.gov/pubmed/35382853
http://dx.doi.org/10.1186/s13023-022-02283-z

Ejemplares similares